Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
1. A method for diagnosing and treating a patient suffering from a subtype of cancer which is resistant to anti-angiogenic therapy, comprising:
obtaining a cancer sample from the patient;
measuring expression levels of a biomarker panel in the cancer sample, wherein the biomarker panel is a ten-biomarker panel comprising at least IGF2, TAP1, SHISA4, ENTPD7, CDR1, SPARC, INS, NUAK1, and MATN3;
determining a cancer sample expression score for the biomarker panel based on the measured expression levels;
comparing the cancer sample expression score to a threshold expression score, derived from a cohort of patients with a known status of responsiveness to an anti-angiogenic agent; and
treating the patient with at least one of a platinum-based chemotherapeutic agent and a mitotic inhibitor, but not an anti-angiogenic agent if the cancer sample expression score is above or equal to the threshold expression score.
2. The method of claim 1 , wherein the cancer is ovarian cancer or colorectal cancer.
3. A method for diagnosing and treating a patient suffering from a subtype of cancer which is resistant to bevacizumab, comprising:
obtaining a cancer sample from the patient;
measuring expression levels of a biomarker panel in the cancer sample, wherein the biomarker panel is a ten-biomarker panel comprising at least IGF2, TAP1, SHISA4, ENTPD7, CDR1, SPARC, INS, NUAK1, and MATN3;
determining a cancer sample expression score for the biomarker panel based on the measured expression levels;
comparing the cancer sample expression score to a threshold expression score, derived from a cohort of patients with a known status of responsiveness to an anti-angiogenic agent; and
treating the patient with at least one of a platinum-based chemotherapeutic agent and a mitotic inhibitor, but not bevacizumab if the cancer sample expression score is above or equal to the threshold expression score.
4. The method of claim 3 , wherein the cancer is ovarian cancer or colorectal cancer.